JP2004525136A - イノシン化合物及び炎症性疾患もしくは再灌流疾患の治療又は予防のためのその使用 - Google Patents

イノシン化合物及び炎症性疾患もしくは再灌流疾患の治療又は予防のためのその使用 Download PDF

Info

Publication number
JP2004525136A
JP2004525136A JP2002574916A JP2002574916A JP2004525136A JP 2004525136 A JP2004525136 A JP 2004525136A JP 2002574916 A JP2002574916 A JP 2002574916A JP 2002574916 A JP2002574916 A JP 2002574916A JP 2004525136 A JP2004525136 A JP 2004525136A
Authority
JP
Japan
Prior art keywords
disease
acyl
pharmaceutically acceptable
compound
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002574916A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004525136A5 (enExample
Inventor
サルズマン，アンドリュー
サボ，チャバ
Original Assignee
イノテック ファーマシューティカルズ コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イノテック ファーマシューティカルズ コーポレーション filed Critical イノテック ファーマシューティカルズ コーポレーション
Publication of JP2004525136A publication Critical patent/JP2004525136A/ja
Publication of JP2004525136A5 publication Critical patent/JP2004525136A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2002574916A 2001-03-26 2002-03-26 イノシン化合物及び炎症性疾患もしくは再灌流疾患の治療又は予防のためのその使用 Withdrawn JP2004525136A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/817,829 US20010053763A1 (en) 1998-12-02 2001-03-26 Method and composition for modulating an immune response
PCT/US2002/009335 WO2002076400A2 (en) 2001-03-26 2002-03-26 Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease

Publications (2)

Publication Number Publication Date
JP2004525136A true JP2004525136A (ja) 2004-08-19
JP2004525136A5 JP2004525136A5 (enExample) 2006-01-12

Family

ID=25223972

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002574916A Withdrawn JP2004525136A (ja) 2001-03-26 2002-03-26 イノシン化合物及び炎症性疾患もしくは再灌流疾患の治療又は予防のためのその使用

Country Status (5)

Country Link
US (1) US20010053763A1 (enExample)
EP (1) EP1383505A4 (enExample)
JP (1) JP2004525136A (enExample)
CA (1) CA2441806A1 (enExample)
WO (1) WO2002076400A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2023132372A1 (enExample) * 2022-01-07 2023-07-13

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010053763A1 (en) * 1998-12-02 2001-12-20 Andrew Salzman Method and composition for modulating an immune response
US6958324B2 (en) * 1998-12-02 2005-10-25 Inotek Pharmaceuticals Corporation Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease
US20050234073A1 (en) * 2003-03-24 2005-10-20 Blumberg Richard S Methods of inhibiting inflammation
US20050090426A1 (en) * 2003-03-24 2005-04-28 Blumberg Richard S. Methods of inhibiting inflammation
CN113398080B (zh) * 2021-06-23 2022-12-02 海南通用康力制药有限公司 一种注射用肌苷及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614504A (en) * 1990-08-01 1997-03-25 The University Of South Florida Method of making inosine monophosphate derivatives and immunopotentiating uses thereof
DK0821692T3 (da) * 1995-04-21 2006-05-22 Univ South Florida Immunopotenserende inosinmonophosphat-5'-nukleotidasemodstandsdygtige derivater og anvendelser deraf
RU2148999C1 (ru) * 1997-05-28 2000-05-20 Санкт-Петербургская государственная медицинская академия Применение этимизола в качестве антиаритмического средства для предупреждения желудочковой экстрасистолии у больных ибс
US20010053763A1 (en) * 1998-12-02 2001-12-20 Andrew Salzman Method and composition for modulating an immune response
WO2000047601A1 (en) * 1999-02-15 2000-08-17 Nippon Shinyaku Co. Ltd. Shortened-chain polynucleotides and process for the preparation thereof
RU2160591C1 (ru) * 1999-06-28 2000-12-20 Казанский государственный медицинский университет Способ терапии бронхиальной астмы у детей

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2023132372A1 (enExample) * 2022-01-07 2023-07-13
WO2023132372A1 (ja) * 2022-01-07 2023-07-13 株式会社マルハチ村松 精神神経疾患を予防または改善するための鰹由来抽出物を含む機能性食品
JP7646137B2 (ja) 2022-01-07 2025-03-17 株式会社マルハチ村松 精神神経疾患を予防または改善するための鰹由来抽出物を含む機能性食品

Also Published As

Publication number Publication date
EP1383505A4 (en) 2006-08-09
WO2002076400A3 (en) 2002-12-05
WO2002076400A2 (en) 2002-10-03
EP1383505A2 (en) 2004-01-28
CA2441806A1 (en) 2002-10-03
US20010053763A1 (en) 2001-12-20

Similar Documents

Publication Publication Date Title
JPH11509181A (ja) 水溶性アデノシンキナーゼ阻害剤
US9533049B2 (en) Method for preparing nanoparticles based on functional amphiphilic molecules or macromolecules, and the use thereof
KR19990022104A (ko) 내독소혈증의 치료 및 예방에 유용한 치환 지당류
JPH08506343A (ja) リキソフラノシル誘導体を含むアデノシンキナーゼ阻害物質
IL183666A (en) Amide prodrug of gemcitabine, pharmaceutical compositions comprising the same and use thereof in the manufacture of medicaments for treatment of susceptible neoplasms
US6958324B2 (en) Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease
EP3546450A1 (en) Piperidine-2,6-dione derivative and treatment for ulcerative colitis
JP2004525136A (ja) イノシン化合物及び炎症性疾患もしくは再灌流疾患の治療又は予防のためのその使用
JP2004525136A5 (enExample)
CA2652633C (en) Crystalline forms of gemcitabine amide prodrug, compositions and use thereof
JPH08503699A (ja) 全身性炎症と炎症性肝炎の治療のためのピリミジンヌクレオチド前駆体
JP2006510633A (ja) 代謝不活性化に耐性の化合物および使用方法
CN101402667B (zh) 糖基化修饰的一氧化氮供体型齐墩果酸类化合物、其制备方法及用途
US20160158267A1 (en) Methods of preventing, reducing or treating macular degeneration
AU2002255927A1 (en) Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease
WO2020038279A1 (zh) 取代吡唑类化合物、其制备方法、药物组合物及用途
JPH02503557A (ja) 治療用ヌクレオシド
CN105330708A (zh) 延胡索乙素衍生物及其制备方法、用途
HK1157195B (en) Applications of triterpenoid saponin compounds in preparation of anti-pathogenic micro-organisms drugs
HK1157195A1 (en) Applications of triterpenoid saponin compounds in preparation of anti-pathogenic micro-organisms drugs
WO2005111053A2 (en) Pharmaceutical compositions having anti-inflammatory activity
JPH0326194B2 (enExample)
BRPI0713615A2 (pt) Formas cristalinas de pró-fármacos de amida de gemcitabina, composições de uso das mesmas

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050324

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050829

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20080425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080425